NasdaqGS - Nasdaq Real Time Price USD
Royalty Pharma plc (RPRX)
55.35 +1.78 (+3.32%)
At close: June 23 at 4:00:00 PM EDT
55.45 +0.10 (+0.18%)
After hours: June 23 at 6:45:44 PM EDT
Trade RPRX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for RPRX
Chart does not reflect overnight price.
- Previous Close
53.57 - Open
53.58 - Bid 50.30 x 100
- Ask 59.02 x 100
- Day's Range
53.31 - 55.49 - 52 Week Range
34.08 - 56.50 - Volume
4,862,026 - Avg. Volume
3,631,282 - Market Cap (intraday)
31.872B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
29.13 - EPS (TTM)
1.90 - Earnings Date (est.) Aug 5, 2026
- Forward Dividend & Yield 0.94 (1.75%)
- Ex-Dividend Date May 15, 2026
- 1y Target Est
59.25
Recent News
View More
Performance Overview
Trailing total returns as of 6/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
RPRX
44.63%
S&P 500 (^GSPC)
7.60%
1-Year Return
RPRX
59.71%
S&P 500 (^GSPC)
22.24%
3-Year Return
RPRX
93.60%
S&P 500 (^GSPC)
69.39%
5-Year Return
RPRX
47.51%
S&P 500 (^GSPC)
73.64%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/22/2026
Market Cap
23.75B
Enterprise Value
31.31B
Trailing P/E
28.19
Forward P/E
44.25
PEG Ratio (5yr expected)
2.00
Price/Sales (ttm)
12.27
Price/Book (mrq)
3.45
Enterprise Value/Revenue
12.83
Enterprise Value/EBITDA
18.43
Financial Highlights
Profitability and Income Statement
Profit Margin
33.86%
Return on Assets (ttm)
5.54%
Return on Equity (ttm)
13.77%
Revenue (ttm)
2.44B
Net Income Avi to Common (ttm)
826.29M
Diluted EPS (ttm)
1.90
Balance Sheet and Cash Flow
Total Cash (mrq)
608.29M
Total Debt/Equity (mrq)
90.32%
Levered Free Cash Flow (ttm)
-980.3M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreRoyalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice TargetRoyalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice TargetRoyalty Pharma Earnings: Resounding Receipt Growth Caps Off Landmark Year
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice TargetRoyalty Pharma Earnings: Portfolio Momentum and Flurry of Commercial Activity Raise Valuation
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice Target